Immunologic Results Demonstrate Statistically Significant Restoration of Key
Immune Function in HIV-Infected Patients
CARLSBAD, Calif., Feb. 28 /PRNewswire-FirstCall/ --
The Immune Response Corporation (Nasdaq: IMNR) announced today new data
presented this week at the Ninth Conference on Retroviruses and Opportunistic
Infections in Seattle. The results were presented by Dr. Fernandez-Cruz,
principal investigator at University General Hospital Gregorio Maranaon in
Madrid, Spain. Out of a total of 243 patients in the multicenter study,
Dr. Fernandez-Cruz examined immune responses in 54 of the patients.
Dr. Fernandez-Cruz reported that CD8+ memory T cells showed a statistically
significant increase in the REMUNE(R) group compared to the Incomplete
Freund's Adjuvant ("IFA") control group (p<0.05). There was also a
statistically significant improvement in the level of HIV-induced
hyperactivation as evidenced by a decrease in activated T cells in the
REMUNE(R) group compared to the IFA control group (p<0.05). The REMUNE(R)
group also showed a statistically significant correlation between Cytotoxic
T cell Lymphocytes ("CTL") precursors and control of virus in the blood
(p<0.05).
As previously reported, the primary endpoint was met for this double blind
placebo controlled 3 year study to determine the effect of REMUNE(R) on the
maintenance of virologic suppression in 243 HIV-infected subjects on antiviral
therapy (See Company Press Release dated August 30, 2001).
"HIV induces hyperactivation of the immune system with destruction of
memory T effector lymphocytes rendering it dysfunctional," said
Dr. Fernandez-Cruz. "These immunologic results from Trial STIR 2102
demonstrate a decrease in immune activation and an increase in memory effector
T cells in REMUNE(R) immunized subjects and support the results previously
reported that therapeutic immunization may, through restoration of the
patients immune system, have a positive impact on delaying virologic failure".
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection. NOTE: Company information can also be
located on the Internet Web site: http://www.imnr.com
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether clinical trials will be successfully
concluded and whether REMUNE(R) will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation's SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 2000 and subsequent
Forms 10-Q. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements, which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
Company News On-Call:
http://www.prnewswire.com/comp/434675.html
CONTACT:
investors, Kathy Lane, +1-760-771-2236, for
The Immune Response Corporation
|
